Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MN-166 First · 1 trial · 2 indications
Participants are allowed to perform an operant task (click on a mouse) in order to receive a dose drug under investigation (oxycodone dose 0 mg, 15 mg, or 30 mg). The drug breakpoint is the maximum number of responses (mouse clicks) the participant was willing to make to receive the drug. Within the context of abuse liability studies, larger breakpoints represent greater abuse potential of a drug.
| Arm | Type | Description |
|---|---|---|
| MN-166 (formerly AV411) First | ACTIVE_COMPARATOR | Participants who began 14-day maintenance on MN-166 (50 mg) first, before switching to Placebo maintenance. |
| Placebo First | PLACEBO_COMPARATOR | Participants who began 14-day maintenance on Placebo first, before switching to MN-166 (50 mg) maintenance. |
| Name | Type | Description |
|---|---|---|
| MN-166 (50 mg) First | DRUG | In this arm of the study participants were first maintained on 50 mg MN-166 BID for approximately 14 days, and were then switched onto placebo maintenance. The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo \& MN-166). |
| Placebo First | DRUG | This arm of the study participants were first maintained on placebo for approximately 14 days, and were then switched onto 50mg MN-166 BID maintenance. . The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo \& MN-166). |
Inclusion Criteria: * Adults between the ages of 21 and 55 * Current opioid dependence according to DSM-IV criteria * currently not seeking treatment Exclusion Criteria: * Female patients that are currently pregnant, or breastfeeding. Lack of effective birth control. * Participants who have a pos...
MN-166 First is an investigational small molecule being studied for the treatment of opioid abuse. It is in Phase 2 clinical development for this indication. The drug is being developed by MediciNova, Inc. and has received Orphan Drug and Fast Track designations from the FDA.
MN-166 First is a small molecule being developed for opioid abuse. The specific molecular target or mechanism of action has not been disclosed in available information. It is currently in Phase 2 clinical trials to evaluate its effects on opioid self-administration in opioid abusers.
MN-166 First is being developed by MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol MNOV. The company is conducting clinical research on this drug for the treatment of opioid abuse.
MN-166 First is in Phase 2 clinical development for opioid abuse. It is an investigational drug and has not been approved by the FDA. The drug has received Orphan Drug and Fast Track designations, which are intended to expedite its development and review.
MN-166 First has one completed Phase 2 clinical trial, NCT01740414, titled 'Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers.' This randomized, double-blind, placebo-controlled study enrolled 28 participants in the United States and investigated the drug's effects on opioid abuse and dependence.
MN-166 First is also known as ibudilast, as indicated by the clinical trial title referencing ibudilast. The drug is being studied under the name MN-166 First for opioid abuse, and it is in Phase 2 development by MediciNova, Inc.